Citations

Clear

6273 citation(s) found for "To, Andrew".

Identification of differentially expressed genes in post‐mortem tissue from African American Alzheimer disease cases and controls
O’Neill, Nicholas K. , Franklin, Erin , Frosch, Matthew P. , Gearing, Marla, Jin, Lee‐Way , Kofler, Julia , Lee, Eddie B, Mayeux, Richard, McKee, Ann C. , Miller, Carol A., Nelson, Peter T. , Perrin, Richard J. , Troncoso, Juan C. , Logue, Mark W. , Labadorf, Adam , Dickson, Dennis W. , Flanagan, Margaret E. , Gearing, Marla , Mayeux, Richard , Murray, Melissa E. , Schneider, Julie A. , Stein, Thor D. , Teich, Andrew F. , Wang, Shih‐Hsiu J. , Mez, Jesse , Farrer, Lindsay A.

Mayo Clinic

Alzheimer's & Dementia | January 3, 2025 | Volume: 20 | Issue: S1 | Pages: No page available

10.1002/alz.091575 Get It

AbstractBackgroundAlthough the rate of Alzheimer’s disease (AD) in African‐ancestry (AA) Americans is higher than that of persons from European‐ancestry (EA) populations, AA participants have been underrepresented in AD neuropathological studies.MethodUtilizing the AD Research Centers (ADRC) infrastructure, we obtained AA donor pre‐frontal cortex (PFC) tissue from brain repositories of 12 ADRC and generated bulk RNA sequencing (RNA‐seq) data for 179 samples that met QC and inclusion criteria. Previously generated PFC RNAseq data were obtained for 28 additional AA donors from the Columbia University ADRC. Differential gene expression was evaluated among 125 donors with a neuropathological diagnosis of AD (NIA‐Reagan intermediate or high likelihood) and 82 neuropathologically confirmed controls using regression models including covariates for age at death, sex, cell‐type frequencies, and RNA integrity number (RIN) calculated with Limma. FDR‐corrected p‐values (padj) were calculated to control for the 33,611 genes examined.ResultA total of 482 genes surpassed the multiple‐testing threshold. The most significant, ADAMTS2 (p = 2.96 × 10‐8, padj = 0.001), showed increased expression in AD cases (see Table/Figure). We note that ADAMTS2 was differentially expressed in a prior EA study of neuropathologically confirmed AD cases and controls (Panitch et al. Molecular Psychiatry 2021). Additionally, a recent analysis of cognitive resilience in EA neuropathological AD cases identified a strong association with ADAMTS2 (See Li et al. AAIC2024 abstract). Of the differentially expressed genes observed in the Panitch et al. EA study, 385 (35%) were nominally significant,65 (5.8%) were corrected significant, and most (89%) of these genes had the same effect direction in the AA cohort. Some of the observed associations appear to be AA specific (e.g., EFR3B, IRS4, and CA12; see Table). Additionally, we found nominally significant (p<0.05) associations with expression of APOE (Log2 fold change [L2FC = ‐0.20, p = 0.012) and several other established AD genes including SORL1 (L2FC = ‐0.10, p = 0.014) and IGF1R(L2FC = 0.11, p = 0.0013).ConclusionThis largest‐ever (to our knowledge) gene expression study of AD in postmortem brain tissue from AA donors implicates many more genes as having a role in AD in this population than previously identified in genome‐wide association studies and provides insight into trans‐ancestry differences risk for AD.
ABCA7‐dependent Neuropeptide‐Y signalling is a resilience mechanism required for synaptic integrity in Alzheimer’s disease
Tayran, Hüseyin, Min, Yuhao , Nelson, Nastasia, Kassara, Nada, Dogru, Rüya Merve, Reyes‐Dumeyer, Dolly , Reddy, Joseph S. , Qiao, Min N, Flaherty, Delaney, Yang, Zikun , İş, Özkan , Ertekin‐Taner, Nilüfer , Mayeux, Richard , Kizil, Caghan, Yılmaz, Elanur , Bhattarai, Prabesh , Wang, Xue , Ma, Yiyi , Coşacak, Mehmet İlyas , Gunasekaran, Tamil Iniyan , Teich, Andrew F. , Vardarajan, Badri Narayan , Tosto, Giuseppe , Kizil, Caghan

Mayo Clinic

Alzheimer's & Dementia | January 3, 2025 | Volume: 20 | Issue: S1 | Pages: No page available

10.1002/alz.089273 Get It

AbstractBackgroundGenetic variations have emerged as crucial players in the etiology of Alzheimer’s disease (AD), and they serve for a better understanding of the disease mechanisms; yet the specific roles of these genetic variants remain uncertain. Animal models with reminiscent disease pathology could uncover previously uncharacterized roles of these genes. Therefore, we generated zebrafish models for AD variants to analyze the in depth molecular and biological functions of these variants.MethodUsing CRISPR/Cas9, we generated a knockout model for abca7, orthologous to human ABCA7. We performed single cell transcriptomics and analyzed the altered genes and molecular pathways in zebrafish. We leveraged data from multiethnic AD cohorts at Mayo Clinic and Columbia University, to perform genetic association studies, co‐expression analyses, in silico interaction mapping, family based variant segregation analyses and epigenetic association studies, and the functional and histological studies in zebrafish.ResultThe abca7± zebrafish reduced astroglial proliferation, synaptic integrity, and microglial response after Aβ42 toxicity. We found that the abca7 loss‐of‐function (LOF) reduced neuropeptide Y (npy) expression as well as Brain‐derived neurotrophic factor (bdnf) and Nerve growth factor receptor (ngfr). Human brain analysis showed reduced NPY in AD, regulatory interaction between NPY and BDNF, genetic variants in NPY associated with AD, and segregation of variants in ABCA7, BDNF and NGFR in families. ABCA7 variants altered the epigenetic codes in NPY, BDNF, and NGFR promoter regions. Human results paralleled with zebrafish findings to indicate an evolutionarily conserved disease mechanism through ABCA7‐NPY signalling axis. NPY administration to zebrafish rescued the phenotypes in abca7 knockout, suggesting a true biological relevance.ConclusionOur results demonstrate a previously unknown link between ABCA7 and NPY in regulation of synaptic integrity and neurogenesis in AD. We propose that ABCA7‐dependent NPY is a resilience factor in vertebrate brains, and this reserve mechanism is impaired in AD.
Distribution of cognitive domains and neuropathology of cases with mild cognitive impairment
Adler, Charles, Mehta, Shyamal H. , Shill, Holly A. , Driver‐Dunckley, Erika, Belden, Christine M. , Beach, Thomas G., Ho, Andrew, Choudhury, Parichita , Shprecher, David , Driver‐Dunckley, Erika , Serrano, Geidy E. , Atri, Alireza , Tremblay, Cécilia

Mayo Clinic

Alzheimer's & Dementia | January 3, 2025 | Volume: 20 | Issue: S3 | Pages: No page available

10.1002/alz.092655 Get It

AbstractBackgroundMild Cognitive Impairment (MCI) is a pre‐dementia state where impaired cognitive domains (memory, executive, visuospatial processing, language) may predict underlying pathology, e.g. Alzheimer’s disease(AD), Lewy body (LB), and other. Delineating neuropathological heterogeneity in MCI and their associations with neuropsychological profiles are important in identifying individuals at risk of further deterioration. We aimed to characterize the neuropathological heterogeneity in cases with a diagnosis of MCI.MethodCases with a final consensus cognitive diagnosis of MCI (n = 128) prior to death were selected from the Arizona Study of Aging and Neurodegenerative disorders (AZSAND). Groups were divided into amnestic (aMCI) and non‐amnestic MCI (naMCI), single and multi‐domain impairment, and specific domain impairment (executive, language, visuospatial) was explored. Presence and severity of neuropathology including AD, LB, cerebral white matter rarefaction (CWMR), cerebral amyloid angiopathy (CAA), cerebral infarcts and microinfarcts (cortical and subcortical), TAR DNA‐binding protein 43 (TDP‐43), and apolipoprotein E (ApoE) status were compared between MCI subtypes.ResultThe number of cases meeting neuropathological criteria for AD was not different between aMCI (36.4%) and naMCI (22.6%) while co‐existent PD was less frequent in aMCI (19.5% vs 38.7%). When compared to naMCI (n = 31), the aMCI (n = 85) group had an older age of death (p = 0.001), less educational years (p = 0.04), a higher number of subcortical infarcts (p = 0.012), a higher regional density of neurofibrillary tangles (p = 0.027) and a lower density of LB (p = 0.015) in the temporal lobe, and CWMR in tended to be more severe in the frontal lobe (p = 0.052). Those with single domain aMCI had less CWMR (p = 0.001) compared to the multidomain. Within the naMCI group, those with single domain MCI had higher proportions of CAA (p = 0.042), and lower LB density (p = 0.019) compared to multidomain. CWMR was more severe (p = 0.026) inConclusionA high heterogeneity was observed between MCI subtypes. While AD pathology was similar between groups, regional anatomical differences were observed. Vascular pathology including subcortical infarcts, CWMR and CAA appear to be commonly associated with both aMCI and naMCI respectively while CWMR was associated with executive dysfunctions. CWMR, CAA and LBs appear to be more frequent in multidomain aMCI and naMCI respectively.
Development of a composite score to predict Lewy body pathology burden
Zhang, Nan , Belden, Christine M. , Adler, Charles, Shill, Holly A. , Mehta, Shyamal H. , Driver‐Dunckley, Erika, Beach, Thomas G. , Reiman, Eric M., Choudhury, Parichita , Chen, Kewei , Tremblay, Cécilia , Ho, Andrew, Driver‐Dunckley, Erika , Shprecher, David , Serrano, Geidy E. , Reiman, Eric M. , Atri, Alireza

Mayo Clinic

Alzheimer's & Dementia | January 3, 2025 | Volume: 20 | Issue: S3 | Pages: No page available

10.1002/alz.092056 Get It

AbstractBackgroundLewy body (LB) diseases can present with overlapping prodromal, cognitive, motor, autonomic or neuropsychiatric symptoms. Intuitively, greater symptom severity should correlate with greater pathological burden, but this has not been consistently shown. LB pathology does not translate to clinical expression in Incidental LB disease. While several composite scores/toolkits utilize overlapping schemes for diagnosis, a composite data‐derived score to predict LB pathologic burden is lacking. We aimed to utilize an autopsy‐confirmed cohort, and validated, brief, and standardized clinical, functional, pathologic assessments, and machine learning (ML)/quantitative modeling techniques to identify clusters and importance rankings among assessments/measures to predict LB pathologic severity and density.MethodA total of 234 subjects with neuropathological finding of LB at autopsy in the Arizona Study of Aging and Neurodegenerative Disorders (AZSAND) who were classified as Cognitively Unimpaired or Mild Cognitive Impairment after their first study clinical evaluation were included. Of these, 145 subjects had complete scores for 32 of 46 measures (clinical, cognitive, behavioral and functional) that were utilized as predictors of LB pathology. Olfactory function was assessed using the University of Pennsylvania Smell Identification Test (UPSIT). LB severity was assessed by the Unified Staging System for Lewy Body Disorders (USSLB). Several ML algorithms and quantitative prediction models were explored and compared: artificial neural network (ANN), partial least square regression (PLSR), support vector regression (SVR), relevance vector regression (RVR) and ensemble forest regression (EFR) with leave‐one‐out (LOO) scheme. Game‐theory based Shapley methods assessed the impact, including rankings, consistency and magnitude, of model predictors.ResultRVR predicted aggregate LB density with large effect size (R2 = 0.691, p<0.00001). ANN predicted USSLB severity stage with large effect size (R2 = 0.74, p<2.5e‐43). All other ML algorithms/models provided substantial prediction. Across all models, UPSIT was the most influential predictor (>65%), followed by Controlled Oral Word Association Test (COWAT) and age.ConclusionThese preliminary and exploratory results support the utilization of ML techniques/models to assess LB pathologic burden with key measures collected in relatively small samples. UPSIT was consistently ranked highest impactful among clinical and functional measures/predictors. Integrated together in ML/data‐derived composites, UPSIT, COWAT and other clinical characteristics may be of antemortem utility to predict USSLB stages.
Frequency of Spondyloarthritis Symptoms Among US Patients With Inflammatory Bowel Disease: A Cross‐Sectional Multi‐Center Study
Ermann, Joerg , Hong, Simon , Stahly, Andrew , Malik, Fardina , Click, Benjamin , Way, Anna, Davis, John M. , Shmais, Manar, Raffals, Laura E., Silfen, Alexa , Dharia, Ishaan , Bhattacharya, Abhik , Moghaddam, Bahar, Mains, Trayton, Kurland, Jayde E., Weisman, Michael H., Davis, John M , Silfen, Alexa , Kuhn, Kristine A , Ermann, Joerg , Dalal, Rahul S. , Scott, Frank I. , Way, Anna, Raffals, Laura E. , Jan, Reem , Rubin, David T. , Patel, Sheena , Kuhn, Kristine A. , Weisman, Michael H.

Mayo Clinic

Arthritis Care & Research | January 3, 2025 | Volume: 77 | Issue: 6 | Pages: 777-784

10.1002/acr.25493 | PMID 39748206 Get It

ObjectiveSpondyloarthritis (SpA) is the most common extraintestinal manifestation of inflammatory bowel disease (IBD). The application of screening tools to detect SpA in patients with IBD may lead to earlier recognition of SpA and affect treatment decisions.MethodsA combination of two previously described SpA screening questionnaires, the Detection of Arthritis in Inflammatory Bowel Disease (DETAIL) and IBD Identification of Spondyloarthritis Questionnaire (IBIS‐Q), was administered to consecutive patients with IBD attending IBD specialty clinics in six US academic medical centers. Demographic data, IBD, and rheumatology history were extracted by chart review.ResultsA total of 669 patients were analyzed. The median age was 40 years (interquartile range [IQR] 30–54) with a median disease duration of 12 years (IQR 6–22) and moderate to severe IBD based on medication exposure and history of bowel surgery. A total of 81 patients (12%) carried a diagnosis of an inflammatory rheumatic disease, whereas 75 (11%) had consulted a rheumatologist during the previous year. Using published cutoffs, 180 out of 669 patients (27%) screened positive with DETAIL, 266 (40%) with IBIS‐Q, and 275 (41%) with either questionnaire. Axial symptoms were more frequently reported than peripheral musculoskeletal complaints. Notably, 189 out of 275 (69%) screen‐positive patients had neither a documented inflammatory rheumatic disease diagnosis nor a visit with a rheumatologist within the past year.ConclusionA substantial proportion of patients with IBD have symptoms suggestive of SpA, and many of these may have undiagnosed SpA. The IBIS‐Q questionnaire appears to identify more potential SpA cases than DETAIL. Strategies are needed to prioritize rheumatology consultations for those patients with IBD who are most likely to benefit.
EUS-guided gallbladder drainage vs dual stent transpapillary gallbladder drainage for management of acute cholecystitis
Amin, Dhruval , Rau, Prashanth , Cooper, Katherine M. , Sayegh, Lea N. , Mostafa, Nouran, Achebe, Ikechukwu , DeVore, Zachary, Gonzalez, Daniella, Stephanie, Stephanie , Mehta, Savant, Marshall, Christopher , Nasser‐Ghodsi, Navine , Marya, Neil B. , Cooper, Katherine M , Sayegh, Lea Nicole , Storm, Andrew C , Mostafa, Nouran, Zivny, Jaroslav, Storm, Andrew C. , Marya, Neil B.

Mayo Clinic

Endoscopy International Open | January 2, 2025 | Volume: 13 | Issue: CP | Pages: No page available

10.1055/a-2509-7076 | PMID 40007656 Get It

Abstract Cholecystectomy (CCY) is the standard treatment for acute cholecystitis. For non-surgical patients, percutaneous cholecystostomy tube (PT-GBD) is recommended but is associated with high readmission rates and poor quality of life. Endoscopic gallbladder decompression techniques, including endoscopic transpapillary gallbladder drainage (ET-GBD) and endoscopic ultrasound-guided gallbladder drainage (EUS-GBD), are alternatives. Studies comparing ET-GBD and EUS-GBD have shown EUS-GBD to have superior outcomes. However, these studies assessed ET-GBD mostly via single transcystic stent placement (SSET-GBD). This study aimed to compare outcomes of dual transcystic stents (DSET-GBD) and EUS-GBD in non-surgical candidates with acute cholecystitis. A multicenter analysis was conducted on patients who underwent ET-GBD or EUS-GBD between January 2019 and January 2023. Data were extracted from electronic medical records and outcomes including technical success, success, adverse events (AEs), and recurrence rates of cholecystitis were measured. Of 129 procedures (56 EUS-GBD; 73 ET-GBD), technical success was achieved in 87.5% of EUS-GBD and 86.3% of ET-GBD attempts. Immediate clinical success was achieved in 98.1% for EUS-GBD and 100% for DSET-GBD. AE rates were similar between the groups. Recurrent cholecystitis rates were 5.3% for EUS-GBD and 8.2% for DSET-GBD (P = 0.692). This study demonstrates that DSET-GBD has similarly low rates of recurrent acute cholecystitis compared with EUS-GBD. DSET-GBD should be considered as an alternative management strategy for management of acute cholecystitis in patients who are unable to undergo CCY.
Structurally Oriented Classification of FOXA1 Alterations Identifies Prostate Cancers with Opposing Clinical Outcomes and Distinct Molecular and Immunologic Subtypes
Hwang, Justin H. , Likasitwatanakul, Pornlada , Deshmukh, Sachin Kumar , Wu, Sharon , Kwon, Jason J. , Toye, Eamon , Moline, David , Evans, Mark G. , Elliott, Andrew , Passow, Rachel , Luo, Christine , John, Emily , McKay, Rana R. , Heath, Elisabeth I. , Nabhan, Chadi , Reizine, Natalie , Orme, Jacob J. , Domingo‐Domenech, Josep , Dehm, Scott M. , Hwang, Justin H , Gandhi, Nishant , McKay, Rana R , Heath, Elisabeth I , Nabhan, Chadi , Reizine, Natalie , Orme, Jacob J , Domingo Domenech, Josep M , Sartor, A Oliver , Baca, Sylvan C , Dehm, Scott M , Antonarakis, Emmanuel S , Elliott, Andrew , Gandhi, Nishant , Sartor, Oliver , Antonarakis, Emmanuel S.

Mayo Clinic

Clinical Cancer Research | January 2, 2025 | Volume: 31 | Issue: 5 | Pages: 936-948

10.1158/1078-0432.ccr-24-3471 | PMID 39745364 Get It

Abstract Purpose: Around 10% to 15% of prostate cancers harbor recurrent aberrations in the Forkhead Box A1 gene, FOXA1, whereby the alteration type and the effect on the forkhead (FKH) domain affect protein function. We developed a FOXA1 classification system to inform clinical management. Experimental Design: A total of 5,014 prostate cancer samples were examined using whole-exome and -transcriptome sequencing from the Caris Life Sciences database. We denoted class 1 FOXA1 alterations as missense and in-frame insertions/deletions with subclasses oriented with respect to the FKH domain. These were in the first part of the FKH domain [class 1A: amino acids (AA) 168–246], within the Wing2 region of FKH (class 1B: AA 247–269), or outside FKH (class 1C: AA 1–167, 270+). Two hotspot missense mutations at R219 were denoted class 2. Class 3 included predicted truncating mutations with subclasses partitioned based on the FKH domain (class 3A: AA 1–269 and class 3B: AA 270+). Class 4 represented FOXA1 amplifications. Real-world overall survival and therapy outcomes were determined from insurance claims. Results: FOXA1 alterations did not influence survival when considered in aggregate but had distinct prognostic effects when stratified by class. In primary prostate samples, class 1A alterations were associated with overall improved survival (HR, 0.57; P = 0.03); a similar trend was seen in metastatic biopsies with class 1B (HR, 0.84; P = 0.09). Conversely, in primary specimens, class 1C exhibited worse survival upon second-generation androgen receptor signaling inhibitor treatment (HR, 1.93; P &lt; 0.001). Class 2 mutations (R219C/S) were enriched in neuroendocrine prostate cancers and were associated with overall poor survival (HR, 2.05; P &lt; 0.001) and worse outcomes to first-line androgen-deprivation therapies (HR, 2.5; P &lt; 0.001). Class 3A alterations indicated improved survival (HR, 0.70; P = 0.01), whereas class 3B alterations portended poor outcomes (HR, 1.50; P &lt; 0.001). Amplifications (class 4) indicated poor outcomes in metastatic samples (HR, 1.48; P = 0.02). Molecularly, different FOXA1 alteration classes harbored distinct mutational and immunologic features as well as unique transcriptional programs. Finally, relative to European Americans, African Americans had increased class 1C alterations, whereas Asian/Pacific Islander patients had increased class 1B alterations. Conclusions: FOXA1 alterations should not be interpreted in aggregate, as different classes are associated with divergent molecular features and clinical outcomes. Our revised classification schema facilitates clinical decision-making for patients with prostate cancer and uncovers important racial differences.
Common Questions and Misconceptions About Energy Drinks: What Does the Scientific Evidence Really Show?
António, José , Antonio, Brandi , Arent, Shawn M. , Candow, Darren G. , Escalante, Guillermo , Evans, Cassandra , Forbes, Scott C. , Fukuda, David H. , Gibbons, Maureen, Jagim, Andrew R. , Kerksick, Chad M. , Kurtz, Jennifer A. , Lillis, Joseph , Lowery, Lonnie , Mastrofini, Gianna F. , Mills, Scotty, Nelson, Michael T. , Pereira, Flavia , Roberts, Justin , Sagner, Michael , Stout, Jeffrey R. , Wells, Adam J. , Forbes, Scott C , Fukuda, David , Jagim, Andrew R , Kerksick, Chad M , Kurtz, Jennifer A , Lowery, Lonnie , Mastrofini, Gianna F , Pereira, Flavia , Roberts, Justin , Stout, Jeffrey R , Wells, Adam , Antonio, Jose , Arent, Shawn M , Harty, Patrick S. , Kalman, Douglas , Tartar, Jaime L.

Mayo Clinic

Nutrients | January 1, 2025 | Volume: 17 | Issue: 1 | Pages: 67

10.3390/nu17010067 | PMID 39796501 Get It

Energy drinks are a commonly consumed beverage, and studies suggest a possible performance-enhancing effect. A Google Scholar search using the keywords “energy drinks” and “exercise” yields numerous results, underscoring the voluminous research on this topic. However, there are questions regarding the effectiveness and safety of energy drinks. These questions include, but are not limited to: (1) What are the main active ingredients in energy drinks? (2) Do energy drinks assist in weight management? (3) Do energy drinks enhance aerobic performance? (4) Do energy drinks enhance athletic speed? (5) Do energy drinks improve reaction time? (6) Do energy drinks enhance lean tissue mass? (7) Can energy drinks improve cognitive performance? (8) Does the acute consumption of energy drinks elevate resting energy expenditure? (9) Is there any evidence to suggest that energy drinks are more effective than an identical serving of caffeine alone? (10) Are there sex differences in the response to energy drink consumption? (11) Do energy drinks affect sleep or sleepiness? (12) Should pregnant women avoid energy drinks? (13) Do energy drinks adversely affect cardiovascular function? (14) Does consuming energy drinks cause brain damage? (15) What are other safety considerations regarding energy drinks? (16) Is there any evidence to suggest that energy drinks are more effective than an identical serving of caffeine alone? (17) If caffeine is the main active ingredient in energy drinks and coffee, why is there a discrepancy in the adverse events reported for each? To address these questions, we performed an evidence-based scientific evaluation of the literature on energy drink supplementation.
Do Factors Influencing Acceptance of Kidney Stone Formers as Donors Predict Subsequent Stone Events?
Keddis, Mira T. , Howard, Matthew R., Zhang, Nan , Quillen, Jaxon , D’Costa, Matthew R. , Khamash, Hasan , Porter, Ivan E. , Stern, Karen , Quillen, Jaxon K, Khamash, Hasan A, Jadlowiec, Caroline , Wadei, Hani M , Porter, Ivan , D'Costa, Matthew , Stern, Karen L , Jadlowiec, Caroline C. , Wadei, Hani M. , Rule, Andrew D.

Mayo Clinic

Clinical Transplantation | December 31, 2024 | Volume: 39 | Issue: 1 | Pages: No page available

10.1111/ctr.70069 | PMID 39737621 Get It

ABSTRACTPurposeThis study aimed to assess whether kidney stone burden and risk factors at the time of kidney donor evaluation were associated with a symptomatic stone event post‐donor evaluation.MethodsWe identified adults evaluated at Mayo Clinic (two sites) (2000–2011) for living kidney donation and had either a personal history or radiological evidence of kidney stone disease. We analyzed demographics, stone risk factors, stone number/size, and the committee's donation decision and reasons. A follow‐up survey (2022–2023) assessed post‐evaluation symptomatic kidney stones and related morbidity.ResultsAmong 412 potential donors with kidney stone disease, 258 donated, 75 did not donate due to kidney stones, and 79 did not donate for other reasons. Multivariable analysis showed that candidates not donating due to stones had higher body mass index (BMI), prior symptomatic kidney stones, multiple stones on imaging, bilateral kidney stones, and diameter of largest stone ≥3 mm. Of 147 who completed the survey, 26 (18%) had a symptomatic kidney stone post‐donor evaluation. Younger age (p = 0.031) and multiple stones on imaging (p = 0.02) were significant predictors of post‐evaluation symptomatic stones regardless of donation status (p = 0.41).ConclusionsStone burden on imaging and prior symptomatic stone events were associated with not donating. Younger age and stone burden on imaging were the primary risk factors for a symptomatic kidney stone event after donor evaluation.
The importance of Fcγ and C-type lectin receptors in host immune responses during Pneumocystis pneumonia
Carmona, Eva M. , Schaefbauer, Kyle, Stelzig, Kimberly E. , Pellegrino, Madeline R., Bindzus, Marc, Limper, Andrew H. , Kottom, Theodore J. , Limper, Andrew H , Carmona, Eva M

Mayo Clinic

Infection and Immunity | December 31, 2024 | Volume: 93 | Issue: 2 | Pages: No page available

10.1128/iai.00276-24 | PMID 39745390 Get It

ABSTRACT Pneumocystis jirovecii pneumonia (PJP) remains a significant cause of morbidity and mortality during AIDS. In AIDS, the absence of CD4 immunity results in exuberant and often fatal PJP. In addition, organism clearance requires a balanced macrophage response since excessive inflammation promotes lung injury and respiratory failure. Corticosteroids given in addition to antibiotics significantly improve outcomes during PJP. However, concerns exist that corticosteroids further suppress immunity and increase co-infections. New strategies to promote killing and clearance of Pneumocystis while balancing lung inflammation are required. Prior studies have shown that innate immunity to Pneumocystis is mediated by C-type lectin receptors (CLRs) on macrophages and involves downstream CARD9 activation. CARD9 can be targeted by a novel specific small molecule inhibitor (BRD5529) that significantly reduces inflammatory signaling by macrophages. CARD9 serves as the central intracellular molecule through which Dectin-1, Dectin-2, Mincle, and other CLRs signal. Dectin-1 CLR is activated through its own intracytoplasmic domain, whereas other innate CLRs (e.g., Dectin-2 and Mincle) require interactions with a common Fc-gamma receptor (FcγR) accessory chain to mediate responses. We now observe that mice double deficient in both Dectin-1 and Fcer1g (which lack the FcγR gamma chain) exhibit markedly reduced organism clearance compared with Card9 −/− infected animals. These mice also possess deficiencies in immunoglobulin (Ig) Fc receptors directly mediating antibody responses, further implicating altered humoral responses in Pneumocystis killing. We further demonstrate in the Pneumocystis pneumonia (PCP) mouse model that BRD5529 administration successfully suppresses inflammatory cytokines. Our data support that innate immune responses through the CLR-CARD9 axis and humoral response act together to mediate effective responses resulting in optimal organism killing and generation of host inflammatory responses. Furthermore, host lung inflammation during PCP may be successfully reduced with a novel CARD9 small molecule inhibitor. IMPORTANCE Pneumocystis pneumonia (PCP) causes severe respiratory impairment in hosts with suppressed immunity, particularly those with CD4 deficiencies, such as HIV. In addition to lymphocytic immunity, both innate and humoral immunities also participate in host defense against Pneumocystis . In the current studies, we defined the relative roles of CLR receptor-mediated inflammation, as well as FcgR-related inflammation and clearance of Pneumocystis organisms. Our studies reveal important roles for CLR activities for inducing lung inflammation, which can be ameliorated with a novel small molecule inhibitor of the CARD9 adaptor protein that is necessary for CLR signaling. In contrast, FcgR has a dominant role in organism clearance, underscoring an integral role of humoral responses for the elimination of this infection.